Endogenous interferon pathways (IFN pathways)

Endogenous interferon pathways represent a critical component of the innate immune system, consisting of Type I (IFN-α, IFN-β), Type II (IFN-γ), and Type III (IFN-λ) interferons and their respective signaling cascades. These pathways are activated upon the detection of viral or bacterial components, leading to the induction of hundreds of interferon-stimulated genes (ISGs) that establish an antiviral state and modulate the adaptive immune response. In clinical practice, these pathways are targeted to treat viral infections (like Hepatitis C) and certain cancers, or suppressed to manage autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. While highly effective, therapeutic manipulation of these pathways often carries significant side effects, including systemic inflammation and hematologic toxicities. Because this entry describes a broad biological pathway rather than a single molecular entity, it is classified as an incorrect target designation for structured pharmacological databases.

Other names

Interferon signaling pathwayType I interferon pathwayType II interferon pathwayType III interferon pathwayJAK-STAT signaling pathway (interferon-mediated)

Drugs modulate these pathways by either supplementing endogenous interferons (agonists), blocking interferon receptors (antagonists), or inhibiting downstream signaling components such as Janus kinases (JAK inhibitors) to suppress or enhance immune responses.